| Natural Coated Microbubbles in the Biosphere | |
| Occurrence of dilute gas-in-liquid emulsions in natural waters | |
| Early work with aqueous carbohydrate gels | |
| Comparison of aqueous soil extracts with carbohydrate gels | |
| Characteristic glycopeptide fraction of natural microbubble surfactant | |
| Physicochemical Properties of Natural Microbubble Surfactant | |
| Ecological chemistry of microbubble surfactant | |
| Surface properties of microbubble-surfactant monolayers | |
| Structure of predominant surfactant components stabilizing natural microbubbles | |
| Stable microbubbles in physiological fluids: competing hypotheses | |
| Physicochemical Properties of Artificial Coated Microbubbles and Nanoparticles | |
| Concentrated gas-in-liquid emulsions in artificial media | |
| Demonstration by laser-light scattering | |
| Concentrated gas-in-liquid emulsions in artificial media | |
| Characterization by photon correlation spectroscopy | |
| Concentrated gas-in-liquid emulsions in artificial media | |
| Review of molecular mechanisms involved in microbubble stabilization | |
| Lipid-Coated Microbubbles and Related Lipid Nanoparticles in Biomedical Studies on Animals | |
| Targeted imaging of tumors, and targeted cavitation therapy, with lipid-coated microbubbles (LCM) | |
| Targeted drug-delivery therapy of tumors using LCM | |
| Proposed mechanism of selective LCM uptake by tumor cells: role of lipoprotein receptor-mediated endocytic pathways | |
| Endocytotic events versus particle size: multidisciplinary analyses demonstrate LCM sizes are mostly submicron | |
| Self-Assembling Mixed-Lipid Microbubbles and Nanoparticles for Clinical Applications | |
| LCM and nanoparticle subpopulations for drug delivery | |
| Composition of LCM governing interplay with nanoparticle subpopulation | |
| Targeted nanoparticle subpopulation: comparison with self-nanoemulsifying drug-delivery systems in pharmaceutical research | |
| Clinical development of a "LCM/nanoparticle-derived" formulation: a nanoemulsion based upon "dispersed LMN" | |
| Selected parenteral lipid nanoemulsions under clinical study: comparison concerning passive accumulation in tumors, active targeting of tumors, and validation status | |
| Supplementary operational benefits concerning "LCM/nanoparticle-derived" formulations: relation to lipid-nanoemulsion structure | |
| "LCM/Nanoparticle-Derived" Nanoemulsions: Biological Lipid Polymorphism, and Receptor Mediated Endocytosis, used for Clinical Study | |
| Biological lipid polymorphs: preferred cubic phase of "dispersed LMN" | |
| Non-lamellar phase(s) facilitating membrane fusion: endocytosis of dispersed LMN | |
| Receptor-mediated endocytosis of (mixed-lipid) dispersed LMN | |
| Further chemotherapy with lipid nanoemulsions: targeting certain proliferative processes, as well as neoplasias, via "lipoprotein receptor"-mediated endocytosis | |
| Related clinical trials and human epidemiological studies | |
| Aspects of future R&D regarding targeted lipid nanoemulsions | |
| Table of Contents provided by Publisher. All Rights Reserved. |
